Therapy Areas: Infectious Diseases
Navrogen signs Cooperative Research and Development Agreement with US Army over infectious diseases
14 September 2021 -

Navrogen, Inc, a privately held preclinical biotechnology company, announced on Monday that it has signed a Cooperative Research and Development Agreement with researchers at The United States Army Medical Research Institute of Infectious Diseases.

The Cooperative Research and Development Agreement intends to test Navrogen's small molecule NK cell activating agents on suppressing propagation of SARS-COV-2. Researchers at The United States Army Medical Research Institute of Infectious Diseases have produced model systems to test agents capable of suppressing SARS-COV-2 infection and propagation. Navrogen has assembled a range of compounds that are able to activate human and rodent NK cells to stimulate humoral immune responses to deal with dysregulated cells.

Login
Username:

Password:


Related Headlines